Jasper Therapeutics Faces Class Action Lawsuit Over Misleading Statements.
ByAinvest
Friday, Nov 7, 2025 3:40 am ET1min read
ATYR--
JSPR--
Jasper Therapeutics is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934. The lawsuit claims the company made false and misleading statements about its manufacturing controls and clinical trials. Shareholders who purchased JSPR shares during the class period (Nov 30, 2023 - Jul 3, 2025) are encouraged to contact the DJS Law Group regarding possible lead plaintiff appointments. The deadline for appointment is Nov 18, 2025.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet